Calcium channel blocker are available in short acting and long acting form. The response of short acting medication is quick as compare to long acting calcium channel blocker drugs. Amlodipine (Norvasc), Diltiazem (Cardizem, Tiazac, others), Felodipine, Isradipine, Nicardipine are the type of calcium channel blocker drug used for the treatment of coronary artery disease, chest pain (angina), irregular heartbeats (arrhythmia) and blood vessel conditions, such as Raynaud's disease.
The global calcium channel blocker drugs market is estimated to be valued at US$ 14,285.3 million in 2022 and expected to exhibit a CAGR of 5.2% over the forecast period (2022-2030).
Figure 1. Global Calcium Channel Blocker Drugs Market Share (%) in Terms of Value, by Region, 2022
To learn more about this report, Request sample copy
Increasing prevalence of hypertension is expected to aid in the growth of the global calcium channel blocker drugs market
According to the World Health Organization 2021, hypertension is a major cause of premature death worldwide.
Moreover, according to the Million Hearts managed by the Centers for Disease Control and Prevention, around 1 out of 2 adults in the U.S. suffer from hypertension. In addition, around 91.7 million adult in the U.S. are recommended prescription medication with lifestyle modifications.
Calcium Channel Blocker Drugs Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 14,285.3 Mn |
Historical Data for: | 2017 to 2021 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 5.2% | 2030 Value Projection: | US$ 21,489.7 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Figure 2. Global Calcium Channel Blocker Drugs Market Share (%), by Drug Class, 2022
To learn more about this report, Request sample copy
Global Calcium Channel Blocker Drugs Market: Restraint
Side effects associated with to calcium channel blockers drug such as, headache, rapid heart rate, edema and constipation are expected to inhibit the market growth during the forecast period for the companies and products.
Key Players
Major players operating in the global calcium channel blocker drugs market include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
Share
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients